Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hugh Watson has a total of 160 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vaccines, Bias, and the Perils of Non-peer-reviewed Studies: Fueling Misinformation and Vaccine Hesitancy

    by Daniel Munblit, Danilo Buonsenso, Piero L Olliaro, Malcolm G Semple, Matthew J Greenhawt, Jon Genuneit, Liat Ashkenazi-Hoffnung, Annelies Wilder-Smith, John O Warner, Aileen Y Chang, et al.

    Unvetted scientific claims about vaccines can spread rapidly and undermine decades of progress in immunization and public trust. A recent non-peer-reviewed analysis, promoted at political hearings, in the documentary “An Inconvenient Study,” and on social media, has been used to suggest that vaccinated children experience higher rates of chronic illness than unvaccinated peers. Despite standard regression models, critical flaws - uncontrolled confounding, exposure misclassification, unequal follow-up, and outcome multiplicity, invalidate causal inference. An independent group of international experts critically appraises this analysis and contrast its claims with the consistent evidence confirming vaccine safety and effectiveness. We also show how poorly designed studies can distort public discourse, amplify misinformation, and fuel vaccine hesitancy. We outline actions to strengthen research integrity, such as transparent data sharing, labeling of non-peer-reviewed content, and evidence-based communication. Safeguarding public health demands that vaccine evidence be methodologically sound, reviewed, and interpreted by qualified experts.

  • Open Access

    A call for sharing individual patient data from trials in hepatology

    by Peter Jepsen, Hugh Watson, Hendrik Vilstrup

  • Viral Kinetics During Acute Chikungunya Virus Infection: Insights Into Potential Role of Monoclonal Antibodies in Viral Clearance and Prophylaxis Using Mathematical Modeling

    by Tey Putita Ou, Sopheak Sorn, Kunthy Nguon, Saraden In, Sreymom Ken, Sowath Ly, Claude Flamand, Nicolas Voirin, Marie Mandron, Hugh Watson, et al.

    Chikungunya virus (CHIKV), an arthritogenic alphavirus, is a significant public health threat in endemic and newly affected regions. This study investigates viral kinetics, immune responses, and the potential of monoclonal antibody (mAb) therapies to mitigate viraemia and transmission during acute CHIKV infection, providing novel insights into early intervention strategies. Using data from 29 patients in Cambodia, serial sampling and viral load quantification revealed that the population‐average peak viral load occurred ~1.87 days prior to symptom onset. Children demonstrated higher peak viral loads and faster replication rates compared to adults, although symptom severity and burden were similar across age groups. IgM antibodies appeared earlier in adults (median: 4.1 days) than in children (median: 5.1 days; p = 0.036). C‐reactive protein (CRP) levels were transiently elevated in about 50% of patients but showed no correlation with disease severity. Mathematical modeling highlighted that prophylactic mAb therapies, when administered 3 days before symptoms onset, could substantially reduce viral load and potentially prevent detectable viraemia. While these findings underscore the potential of mAbs as an early therapeutic strategy, further studies are necessary to evaluate the robustness of these results and assess their practical implications to curb CHIKV outbreaks by minimizing viraemia and presymptomatic transmission.


  • Global ultrasound synovitis scores reflect symptom severity and patient outcomes in chronic chikungunya disease

    by Hugh Watson, Juana del Valle-Mendoza, Miguel Angel Aguilar-Luis, Ronald Aquino-Ortega, Wilmer Silva-Caso, Yordi Tarazona-Castro, Andrea Nizzardo, Giulia Calusi, Marie Mandron, Esteban Puentes, et al.

    Objectives: Acute chikungunya virus infection often leads to chronic post-infection arthritis, but investigation and evaluation of treatment is hampered by the subjectivity of symptoms. This study was designed to evaluate ultrasound scores and serum inflammatory markers as objective measures for the severity of chronic post-chikungunya arthritis. Methods: Patients with acute chikungunya virus infection were enrolled in a prospective study and followed up at 3, 6 and 12 months. Assessments included both a physical exam and standardized ultrasound examination of 40 joints. Symptom severity and patient reported outcomes were recorded, and serum inflammatory markers were measured. Global ultrasound synovitis and tenosynovitis scores were calculated and correlation of ultrasound and serum markers with clinical symptoms and outcomes was analysed. Results: Sixty patients (mean age 34 years, 67% female) were followed up. Widespread joint involvement was observed in the acute infection phase. This was followed by increasing involvement of small joints contributing to persistent symptoms in 57% of patients at 3 months and 30% at 12 months. Global ultrasound scores for synovitis at 3 months correlated with tender joint counts (r = 0.54, P < 0.0001), pain severity (r = 0.59, P < 0.0001), musculoskeletal stiffness (r = 0.42, P < 0.001) and RAPID3 scores (r = 0.59, P < 0.0001), confirmed at 6 and 12 months. Serum inflammatory markers were poorly associated with persistent symptoms during follow-up. Conclusion: Global ultrasound scores for synovitis were found to be a relevant measure to support clinical observations in studies of chronic post-chikungunya joint disease.


  • Open Access

    Viral kinetics during acute chikungunya virus infection

    by Tey Putita Ou, Sopheak Sorn, Kunthy Nguon, Saraden In, Sreymom Ken, Sowath Ly, Claude Flamand, Nicolas Voirin, Marie Mandron, Hugh Watson, et al.

    Chikungunya virus (CHIKV), an arthritogenic alphavirus, is a significant public health threat in endemic and newly affected regions. This study investigates viral kinetics, immune responses, and the potential of monoclonal antibody (mAb) therapies to mitigate viraemia and transmission during acute CHIKV infection, providing novel insights into early intervention strategies. Using data from 29 patients in Cambodia, serial sampling and viral load quantification revealed that the population-average peak viral load occurred approximately 1.87 days prior to symptom onset. Children demonstrated higher peak viral loads and faster replication rates compared to adults, although symptom severity and burden were similar across age groups. IgM antibodies appeared earlier in adults (median: 4.1 days) than in children (median: 5.1 days; p = 0.036). C-reactive protein (CRP) levels were transiently elevated in about 50% of patients but showed no correlation with disease severity. Mathematical modeling highlighted that prophylactic mAb therapies, when administered three days before symptoms onset, could substantially reduce viral load and potentially prevent detectable viraemia. While these findings underscore the potential of mAbs as an early therapeutic strategy, further studies are necessary to evaluate the robustness of these results and assess their practical implications to curb CHIKV outbreaks by minimizing viraemia and pre-symptomatic transmission.

  • Delta in Denmark: prevalence of hepatitis delta virus infection

    by Hugh Watson, Peter Jepsen, Hendrik Vilstrup, Henrik Krarup

    Hepatitis delta virus (HDV) infection has an aggressive disease course and is the most difficult to treat of the human hepatitis viruses. In Denmark, as in many countries, the national prevalence of HDV has not been established. Based on diagnoses and laboratory test results in national healthcare registries, we estimated that the prevalence of current HDV infection amongst patients with chronic hepatitis B was 3.1% and the general population prevalence approximately 4 in 100,000.


  • Open Access

    Randomized clinical trial on safety of the natriuretic peptide ularitide as treatment of refractory cirrhotic ascites

    by Rasmus H. Gantzel, Emilie E. Møller, Niels K. Aagaard, Hugh Watson, Peter Jepsen, Henning Grønbæk

    Background: Sodium and water retention is a mainstay of the pathophysiology leading to ascites formation in patients with advanced cirrhosis. Refractory ascites denotes the most severe ascites status with limited treatment options and a poor prognosis. We investigated the efficacy and safety of the natriuretic peptide ularitide in patients with refractory cirrhotic ascites. Methods: We conducted a randomized placebo-controlled trial investigating ularitide to manage refractory ascites. Until trial termination after interim analyses, we randomized 17 participants in a 2:1 ratio between ularitide (n=11) and placebo (n=6). While hospitalized, the participants received treatment for up to 48 hours. The primary efficacy endpoint was a change in renal water excretion, and secondary end points included changes in renal sodium excretion rate and body weight. The starting dose was 30 ng/kg/min, though later reduced to 20 for safety reasons. Results: In contrast to the study hypothesis, the mean urine production decreased after 24 hours of ularitide treatment compared with the baseline level (22.8 vs. 47.5 mL/h, p=0.04) and decreased more in participants randomized to ularitide than placebo (24.7 vs. −6.2 mL/h, p=0.05). Ularitide did not increase the renal sodium excretion rate or reduce the weight gain. The incidence rate ratio of adverse reactions in ularitide versus placebo was 8.5 (95% CI: 2–35, p=0.003). Participants treated with ularitide developed serious blood pressure reductions, impacting their renal responsiveness. Conclusions: Ularitide in doses of 20–30 ng/kg/min did not benefit urine production and renal sodium excretion rate in patients with refractory ascites. The participants randomized to ularitide overall developed more adverse reactions than placebo. EudraCT no. 2019-002268-28.


  • Open Access

    Non-Selective Beta-Blockers and Risk of Sepsis in Patients with Cirrhosis and Ascites: Results from a Large Observational Study

    by Morten Daniel Jensen, Hugh Watson, Hendrik Vilstrup, Peter Jepsen

    Background and Aims: Previous studies have not been able to determine whether non-selective beta-blockers (NSBB) reduce the risk of sepsis in cirrhosis. We aimed to examine this question with data from 1198 patients with cirrhosis and ascites included in clinical studies of satavaptan, a vasopressin receptor antagonist with no effect on infection risk. Methods: Risk of sepsis was estimated for NSBB users vs nonusers. Patients were examined every four weeks, or in relation to hospitalization, for the one-year duration of the trials. We computed the cumulative risk of sepsis for patients who did vs did not use NSBB at baseline. We used Cox regression to compare hazard rates of sepsis between current users and nonusers, accounting for changes in NSBB use over time. We adjusted for patient sex and age, MELD-Na score, albumin, use of antibiotics, use of proton pump inhibitors, cirrhosis etiology, history of variceal bleeding or SBP, severity of ascites and HE, HCC, other cancers, and diabetes, while stratifying on geographical region. Results: Of the 1198 patients, 54% used NSBB at some time. There were 56 sepsis episodes. The 1-year risk of sepsis was reduced to 5.7% (95% confidence interval [CI] 2.8– 8.6) in baseline NSBB users vs 11.6% (95% CI 7.0– 15.9) in baseline nonusers. The hazard ratio of sepsis for current NSBB users vs current nonusers was reduced to 0.5 (95% CI 0.3– 0.8) and after adjustment to 0.7 (95% CI 0.4– 1.3). Conclusion: NSBB use may reduce the risk of sepsis in patients with cirrhosis and ascites, but the precision of the estimate was limited by the number of episodes of sepsis.


  • Open Access

    Determinants of Health-Related Quality of Life in Chronic Chikungunya Disease in Guadeloupe

    by Fabrice Simon, Rémi Bossy, Denise Federico, Julien Dezaunay, Anne-Laurence Demoux, Nadia Rugard, Giulia Calusi, Andrea Nizzardo, Hugh Watson, Franciane Gane-Troplent

    Chronic chikungunya disease is associated with a poor quality of life and a variety of symptoms, not restricted to the musculoskeletal system. Patients with chronic chikungunya disease in Guadeloupe were evaluated in order to identify the main factors determining the quality of life. Patients were followed up at a mean of 36 months after chikungunya infection, undergoing detailed clinical examination for musculoskeletal involvement, with assessment of subjective symptoms and the impact on mood, physical activity, and quality of life (SF12). Patients had extensive musculoskeletal involvement shown by tenderness in 9 ± 4 joints and stiffness in 5 ± 4 joints. SF12 physical and mental component scores showed a poor health-related quality of life. Measures of joint pain, stiffness, and inflammation contributed to impaired quality of life scores. In addition, fatigue and interrupted sleep appeared to be important predictors for physical aspects of quality of life. The emergence of anxiodepressive syndromes post-chikungunya infection was associated with both physical and mental component scores of SF12. These data confirm that musculoskeletal symptoms are not the only determinants of quality of life in chronic chikungunya disease. Follow-up of patients should include assessment and management of fatigue, poor sleep quality, and anxiodepressive syndromes.


  • Open Access

    Development and validation of the Cirrhotic Ascites Severity model—A patient‐reported outcome‐based model to predict 1‐year mortality

    by Rasmus Hvidbjerg Gantzel, Niels Kristian Aagaard, Hendrik Vilstrup, Hugh Watson, Henning Grønbæk, Peter Jepsen

    Ascites formation is a sign of decompensation of cirrhosis and heralds a poor prognosis. The widely used standard binary classification of ascites as diuretic‐responsive or refractory does not cover the spectrum of ascites and has limited prognostic information. We developed the Cirrhotic Ascites Severity (CIRAS) model to predict 1‐year mortality among 465 patients randomized to placebo in the satavaptan trials investigating treatment of cirrhotic ascites. We used multivariable logistic regression to derive the CIRAS model based on these variables: ascites discomfort score (≤50 or >50), plasma sodium (≥140, 133–139, 125–132, or Conclusions: The CIRAS model based on simple ascites‐relevant data is an easily applicable and patient‐centered way to describe the severity and prognosis of all ascites grades. It carries more prognostic information than today's label of “refractory ascites” and forms the basis for earlier and better clinical decisions related to ascites management.